Mumbai: Kiran Mazumdar-Shaw has named her niece, Claire Mazumdar (in pic), as her successor at Biocon.
In a post on X, the Biocon founder and chairperson clarified that she will continue her role at the helm of the biotechnology company, and that the succession will be gradual. "Claire will transition into my role at the right time, so not planning to hang up my boots just yet," she wrote.
Mazumdar, 37, is the founding chief executive officer of Bicara Therapeutics, a Nasdaq-listed company incubated by Biocon. Bicara, which focuses on novel cancer therapies, has a market capitalisation of over $1.5 billion.
A Bachelor of Science in biological engineering from MIT, Mazumdar earned her MBA from Stanford Graduate School of Business and a PhD in cancer biology from Stanford School of Medicine.
Her research in tumour immunology and cancer epigenetics has been published in Nature, Cell Stem Cell and Cancer Cell. She has led business development and corporate strategy at Rheos Medicines, where she supported a partnership with Roche.
Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to combine the precision of tumour-targeting antibodies with tumour microenvironment modulators.
Assembly Elections 2026
Election Results 2026 Live Updates: Who's ahead in which state
West Bengal Election Results 2026 Live Updates
TN Election Result 2026 Live Updates
Mazumdar, 37, is the founding chief executive officer of Bicara Therapeutics, a Nasdaq-listed company incubated by Biocon. Bicara, which focuses on novel cancer therapies, has a market capitalisation of over $1.5 billion.
A Bachelor of Science in biological engineering from MIT, Mazumdar earned her MBA from Stanford Graduate School of Business and a PhD in cancer biology from Stanford School of Medicine.
Her research in tumour immunology and cancer epigenetics has been published in Nature, Cell Stem Cell and Cancer Cell. She has led business development and corporate strategy at Rheos Medicines, where she supported a partnership with Roche.
Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to combine the precision of tumour-targeting antibodies with tumour microenvironment modulators.
